Oruka Therapeutics, Inc. (ORKA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$49.5M
Cash & Equivalents
$23.6M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$5,234M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-01-01 | Phase1 Readout | — |
| 2027-06-01 | Phase2 Readout | — |
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07474792 | Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis | PHASE2 | Recruiting | 160 |
| NCT07090330 | ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis | PHASE2 | Active Not Recruiting | 80 |
| NCT07449702 | An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis | PHASE2 | Recruiting | 240 |
| NCT07290569 | Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis | PHASE2 | Recruiting | 160 |
| NCT06944379 | ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose | PHASE1 | Active Not Recruiting | 24 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.